Prime Medicine, Inc. (PRME) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Prime Medicine, Inc. is a biotechnology company developing Prime Editing technology for curative genetic therapies. The company is currently focused on advancing its in vivo liver franchise (Wilson's Disease and Alpha-1 Antitrypsin Deficiency) and its Cystic Fibrosis program. As of the filing date, the company remains in the pre-commercial stage with no product sales revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $1,225 | $209 | $3,794 | $800 |
| Net Loss | $(50,582) | $(52,518) | $(155,063) | $(153,606) |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(0.44) | $(1.11) | $(1.34) |
| Operating Expenses | $55,198 | $54,441 | $163,536 | $159,045 |
| Cash, Cash Equivalents & Investments | $213,300 | $189,971 | $213,300 | $189,971 |
| Restricted Cash | $13,691 | $14,062 | $13,691 | $14,062 |
| Accumulated Deficit | $(842,275) | $(644,936) | $(842,275) | $(644,936) |
Note: Revenue is derived primarily from collaboration agreements. The company reported $1.179 million in related-party collaboration revenue in Q3 2025.
Material Changes vs. Prior Period
- Capital Raise: In August 2025, the company completed a public offering of 43.7 million shares at $3.30 per share, netting approximately $138.4 million after costs. This significantly bolstered liquidity compared to the prior year.
- Revenue Growth: Total revenue for the nine months ended September 30, 2025, increased to $3.8 million from $0.8 million in the same period in 2024, driven by collaboration revenue recognition.
- Expense Management: Personnel expenses decreased by $6.0 million (9M 2025 vs. 2024) due to a workforce reduction announced in May 2025. However, facility-related expenses increased by $9.7 million due to the expansion and build-out of laboratory space at 60 First Street and 500 Arsenal Street.
- Strategic Shift: Research costs decreased by $5.2 million as the company deprioritized its Chronic Granulomatous Disease (CGD) programs to focus on its in vivo liver franchise.
- Stock-Based Compensation: Total stock-based compensation expense increased to $24.8 million for the nine months ended September 30, 2025, from $20.1 million in the prior year period, partly due to a one-time repricing of stock options and the issuance of restricted stock units.
Guidance, Outlook, and Risks
- Cash Runway: Management expects cash, cash equivalents, and investments of $213.3 million (excluding restricted cash) to be sufficient to fund operations for at least the next twelve months, with a belief that resources will extend into 2027.
- Development Timeline: The company targets IND/CTA filings in the first half of 2026 for Wilson's Disease and the middle of 2026 for Alpha-1 Antitrypsin Deficiency (AATD).
- PM359 Data: Positive initial data was reported for PM359 in a Phase 1/2 trial for Chronic Granulomatous Disease (CGD), showing high dihydrorhodamine positivity in dosed patients.
- Legal Proceedings: The company is engaged in arbitration with Beam Therapeutics regarding the AATD program. Beam alleges breach of contract and trade secret misappropriation. The outcome could result in monetary damages or an order to cease work on the AATD program.
- Government Shutdown Risk: The filing highlights risks associated with the U.S. federal government shutdown (effective October 1, 2025), which could delay FDA reviews and regulatory approvals.
- Macroeconomic Risks: Risks include potential tariffs on pharmaceutical raw materials and disruptions in capital markets.
Investor Verification Checklist
- Arbitration Outcome: Monitor the status of the consolidated arbitration with Beam Therapeutics regarding the AATD program and potential impact on the pipeline.
- Cash Burn Rate: Verify the sustainability of the $213.3 million cash position against the increased facility costs and R&D spend for the liver franchise.
- Regulatory Timeline: Confirm the ability to meet the targeted 2026 IND/CTA filing dates for Wilson's Disease and AATD amidst potential FDA delays due to government funding issues.
- Stock Option Repricing: Review the long-term impact of the August 2025 option repricing on future stock-based compensation expenses and employee retention.
- Collaboration Revenue: Track the recognition of deferred revenue from the Bristol-Myers Squibb (BMS) and Cystic Fibrosis Foundation (CFF) agreements.